Actively Recruiting

Phase 4
Age: 40Years +
All Genders
NCT04715568

Secondhand Tobacco Smoke and Cardiovascular Disease

Led by University of California, San Francisco · Updated on 2025-07-23

100

Participants Needed

1

Research Sites

300 weeks

Total Duration

On this page

Sponsors

U

University of California, San Francisco

Lead Sponsor

F

Flight Attendant Medical Research Institute

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to secondhand tobacco smoke.

CONDITIONS

Official Title

Secondhand Tobacco Smoke and Cardiovascular Disease

Who Can Participate

Age: 40Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to understand and provide informed consent
  • Adults aged 40 years or older
  • History of occupational exposure to secondhand tobacco smoke for at least 5 years, such as flight attendants before aircraft smoking bans or casino workers in smoky casinos
  • Never smoked or remote light smoking history defined as less than 1 pack-year lifetime and no smoking for at least 20 years before enrollment
Not Eligible

You will not qualify if you...

  • Unable or unwilling to provide written informed consent or follow study procedures
  • Pregnant, breastfeeding, or planning pregnancy
  • Current use of ACE inhibitors or angiotensin receptor blockers
  • Known intolerance to ACE inhibitors or ARBs
  • History of angioedema
  • Medical reason for ACE inhibitors or ARBs such as prior heart attack or cardiomyopathy
  • Low blood pressure (systolic <90 mm Hg or diastolic <60 mm Hg)
  • Severe renal artery narrowing (>70%) or poor kidney function (creatinine clearance <30 mL/min)
  • Regular use of NSAIDs daily for 5 or more days per week over one month
  • Use of potassium supplements or potassium-sparing diuretics, or high potassium levels (≥5.0 mEq/dL) at baseline
  • History of overt cardiovascular disease including angina, symptomatic coronary artery disease, congestive heart failure with reduced ejection fraction, significant heart valve disease, congenital heart disease, or frequent abnormal heart rhythms
  • History of pulmonary disease that may affect study including moderate or worse asthma, COPD, emphysema, interstitial lung disease, or pulmonary hypertension
  • Neuromuscular disorders or physical disabilities preventing exercise testing
  • Significant recreational drug use except marijuana, with recent or frequent use restrictions
  • Other uncontrolled chronic illnesses interfering with study
  • Failure to keep appointments or non-adherence
  • Participation in other interventional studies
  • Body mass index less than 15 or greater than 40 kg/m2
  • Presence of implanted metallic objects incompatible with MRI scanning such as pacemakers or defibrillators

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

San Francisco Veterans' Affairs Medical Center

San Francisco, California, United States, 94121

Actively Recruiting

Loading map...

Research Team

M

Mehrdad Arjomandi, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here